INSM Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of 16.99%. Insmed, Inc.'s return on equity of -192.35% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Insmed, Inc. has a consensus price target of $212.53, signalling upside risk potential of 52.46%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 42.62%. Given that Insmed, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Insmed, Inc. has a beta of 1.131, which suggesting that the stock is 13.112% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Insmed, Inc.'s net income of -$328.5M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 45.72x versus 11.52x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Biogen, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of -2.24%. Insmed, Inc.'s return on equity of -192.35% beat Biogen, Inc.'s return on equity of 7.36%.

Insmed, Inc. has a consensus price target of $212.53, signalling upside risk potential of 52.46%. On the other hand Biogen, Inc. has an analysts' consensus of $205.67 which suggests that it could grow by 7.97%. Given that Insmed, Inc. has higher upside potential than Biogen, Inc., analysts believe Insmed, Inc. is more attractive than Biogen, Inc..

Insmed, Inc. has a beta of 1.131, which suggesting that the stock is 13.112% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.865%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are smaller than Biogen, Inc. quarterly revenues of $2.2B. Insmed, Inc.'s net income of -$328.5M is lower than Biogen, Inc.'s net income of -$48.9M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 21.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 45.72x versus 2.93x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of 0.91%. Insmed, Inc.'s return on equity of -192.35% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.

Insmed, Inc. has a consensus price target of $212.53, signalling upside risk potential of 52.46%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.91%. Given that Insmed, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than Amicus Therapeutics, Inc..

Insmed, Inc. has a beta of 1.131, which suggesting that the stock is 13.112% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.430, suggesting its less volatile than the S&P 500 by 56.973%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Insmed, Inc.'s net income of -$328.5M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 45.72x versus 7.03x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of -18.24%. Insmed, Inc.'s return on equity of -192.35% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.

Insmed, Inc. has a consensus price target of $212.53, signalling upside risk potential of 52.46%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $667.57 which suggests that it could grow by 54.7%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Insmed, Inc..

Insmed, Inc. has a beta of 1.131, which suggesting that the stock is 13.112% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -0.970, suggesting its less volatile than the S&P 500 by 196.976%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. Insmed, Inc.'s net income of -$328.5M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 45.72x versus 10.09x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.